Activation of the NKG2D and FcγRIIIa axes by 23ME-01473 provided augmented immune activation and tumor growth control, highlighting the promise of 23ME-01473 to induce antitumor immunity in patients with cancer. This evidence concerns the gene KLRK1 and neoplasm.